Mariner’s Neurogene NGNE Stock Holding History

Mariner’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$336K	Buy	+16,687	New	+$323K	﹤0.01%	2765
2025 Q1	–	Sell	-10,475	Closed	-$239K	–	3542
2024 Q4	$239K	Buy	+10,475	New	+$390K	﹤0.01%	2842

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Mariner's NGNE Position: Q1 2026 in Review

Mariner opened a new position in Neurogene (NGNE) in Q1 2026: 16,687 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #2765 among its holdings. This is a return to the name: Mariner previously reported a position in NGNE as recently as Q4 2024.

Mariner first reported a position in NGNE in Q4 2024 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

Mariner held 16,687 shares of Neurogene worth $336K as of Q1 2026.
Neurogene was a new Mariner position in Q1 2026.
Neurogene made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2765 holding.
Mariner first reported a position in Neurogene in Q4 2024 and has held it in 2 quarters since.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.